Tvardi Therapeutics (LTS:0HTC) Buildings And Improvements : £0.00 Mil (As of Mar. 2025)

View and export this data going back to 2025. Start your Free Trial

What is Tvardi Therapeutics Buildings And Improvements?

Tvardi Therapeutics Buildings And Improvements Historical Data

The historical data trend for Tvardi Therapeutics's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tvardi Therapeutics Buildings And Improvements Chart

Tvardi Therapeutics Annual Data

Trend

Dec22

Dec23

Buildings And Improvements

Tvardi Therapeutics Quarterly Data
	Dec22	Dec23	Mar24	Sep24	Mar25
Buildings And Improvements	-	-	-	-	-

Tvardi Therapeutics Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Tvardi Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tvardi Therapeutics Inc (LTS:0HTC) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

TVRD:USA 69C:Germany

Address

3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478

Website

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Tvardi Therapeutics Headlines

No Headlines